+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer



Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer



Chinese Journal of Cancer 30(6): 407-414



Studies have shown cell-free microRNA (miRNA) circulating in the serum and plasma with specific expression in cancer, indicating the potential of using miRNAs as biomarkers for cancer diagnosis and therapy. This study was to investigate whether plasma miRNA-21 (miR-21) can be used as a biomarker for the early detection of non-small cell lung cancer (NSCLC) and to explore its association with clinicopathologic features and sensitivity to platinum-based chemotherapy. We used real-time RT-PCR to investigate the expression of miR-21 in the plasma of 63 NSCLC patients and 30 healthy controls and correlated the findings with early diagnosis, pathologic parameters, and treatment. Thirty-five patients (stages IIIB and IV) were evaluable for chemotherapeutic responses: 11 had partial response (PR); 24 had stable and progressive disease (SD+ PD). Plasma miR-21 was significantly higher in NSCLC patients than in age- and sex-matched controls (P < 0.001). miR-21 was related to TNM stage (P < 0.001), but not related to age, sex, smoking status, histological classification, lymph node status, and metastasis (all P > 0.05). This marker yielded a receiver operating characteristic (ROC) curve area of 0.775 (95% CI: 0.681- 0.868) with 76.2% sensitivity and 70.0% specificity. Importantly, miR-21 plasma levels in PR samples were several folds lower than that in SD plus PD samples (P = 0.049), and were close to that in healthy controls (P = 0.130). Plasma miR-21 can serve as a circulating tumor biomarker for the early diagnosis of NSCLC and is related to the sensitivity to platinum-base chemotherapy.

(PDF emailed within 1 workday: $29.90)

Accession: 053669731

Download citation: RISBibTeXText

PMID: 21627863


Related references

Identification of plasma microRna-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chinese Journal of Cancer 30(6): 407-414, 2011

Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer. Oncology 94(5): 311-323, 2018

30PD Novel plasma circulating microRNA signature for early detection of non-small cell lung cancer in liquid biopsy. Journal of Thoracic Oncology 11(4 Suppl.): S68-S68, 2016

MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer. Plos One 10(8): E0134220, 2016

Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer. Oncology Letters 13(3): 1256-1263, 2017

Detection of epidermal growth factor receptor mutation in plasma as a biomarker in Chinese patients with early-stage non-small cell lung cancer. Oncotargets and Therapy 8: 3289-3296, 2015

Identification of circulating long non-coding RNA GAS5 as a potential biomarker for non-small cell lung cancer diagnosisnon-small cell lung cancer, long non-coding RNA, plasma, GAS5, biomarker. International Journal of Oncology 50(5): 1729-1738, 2017

Identification a novel clinical biomarker in early diagnosis of human non-small cell lung cancer. Glycoconjugate Journal 2019, 2019

Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 35(5): E271, 2013

Carbonic anhydrase 1 is a promising biomarker for early detection of non-small cell lung cancer. Tumour Biology 37(1): 553-559, 2017

MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in non-small cell lung cancer by targeting RUNX2. Tumour Biology 37(1): 1197-1204, 2017

MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1. European Review for Medical and Pharmacological Sciences 20(22): 4697-4704, 2017

MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4. Diagnostic Pathology 9: 143, 2015

Identification and Validation of Serum MicroRna Biomarker for Early Detection of Gastric Cancer. Gastroenterology 146(5): S-31, 2014

MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer. Anti-Cancer Drugs 28(8): 852-860, 2017